GlucoTrack delays third-quarter report over derivative valuations
GCTK•GlucoTrack delayed its Form 10-Q for the quarter ended September 30, 2026, while it completes accounting and valuations involving derivative liabilities. It expects to file within the five-calendar-day extension period and expects a net loss of approximately $29 million, up about $13.3 million.
1. Filing delay and outlook
GlucoTrack delayed its quarterly report pending accounting and valuations involving derivative liabilities and expects to file within the five-calendar-day extension period. It projects operating expenses of approximately $17.2 million, up from $12.6 million a year earlier, and net financing-related expenses of approximately $11.8 million, compared with $3.1 million; the expected net loss of approximately $29 million reflects the Lokahi merger and financing transactions.




